Acute severe visual decrease after photodynamic therapy with verteporfin: spectral-domain OCT features.

In this report, spectral-domain optical coherence tomography (OCT) was used to characterize the acute morphologic alterations that occur when photodynamic therapy with verteporfin results in an acute severe visual decrease. The clinical and imaging records of a patient with neovascular age-related macular degeneration who suffered this complication were reviewed. Using spectral-domain OCT, two relatively distinct subretinal fluid compartments were visualized: a sparsely hyperreflective pocket of subretinal fluid overlying the fibrovascular pigment epithelial detachment, consistent with fibrinous exudation, and a more homogeneously hyporeflective compartment at the periphery of the choroidal neovascular lesion, consistent with serous exudation. The higher axial resolution, and greater sensitivity, of spectral-domain OCT allows improved visualization of the subretinal space. As experience with spectral-domain OCT grows, new parameters will emerge-such as those related to subretinal fluid-that will facilitate improvements in both the qualitative and quantitative evaluation of macular disease.

[1]  Christian Ahlers,et al.  Identification of optical density ratios in subretinal fluid as a clinically relevant biomarker in exudative macular disease. , 2009, Investigative ophthalmology & visual science.

[2]  S. Michels,et al.  Combination of verteporfin photodynamic therapy and ranibizumab: effects on retinal anatomy, choroidal perfusion and visual function in the protect study , 2008, British Journal of Ophthalmology.

[3]  U. Schmidt-Erfurth,et al.  Same-day administration of verteporfin and ranibizumab 0.5 mg in patients with choroidal neovascularisation due to age-related macular degeneration , 2008, British Journal of Ophthalmology.

[4]  S. Kishi,et al.  Tomographic features of serous retinal detachment with multilobular dye pooling in acute Vogt-Koyanagi-Harada disease. , 2007, American journal of ophthalmology.

[5]  U. Schmidt-Erfurth,et al.  Management of neovascular age-related macular degeneration , 2007, Progress in Retinal and Eye Research.

[6]  U. Schmidt-Erfurth,et al.  Time course and morphology of vascular effects associated with photodynamic therapy. , 2005, Ophthalmology.

[7]  S. Wolf,et al.  Complications after photodynamic therapy. , 2005, Archives of ophthalmology.

[8]  Michael Stur,et al.  Acute severe visual acuity decrease after photodynamic therapy with verteporfin: case reports from randomized clinical trials-TAP and VIP report no. 3. , 2004, American journal of ophthalmology.

[9]  George A. Williams,et al.  IMMEDIATE INDOCYANINE GREEN ANGIOGRAPHY AND OPTICAL COHERENCE TOMOGRAPHY EVALUATION AFTER PHOTODYNAMIC THERAPY FOR SUBFOVEAL CHOROIDAL NEOVASCULARIZATION , 2003, Retina.

[10]  Carmen A Puliafito,et al.  Optical coherence tomography findings following photodynamic therapy of choroidal neovascularization. , 2002, American journal of ophthalmology.

[11]  N. Bressler,et al.  Loculated fluid. A previously undescribed fluorescein angiographic finding in choroidal neovascularization associated with macular degeneration. Macular Photocoagulation Study Reading Center. , 1991, Archives of ophthalmology.

[12]  N. Bressler,et al.  Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. , 1999, Archives of ophthalmology.